Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 8:12:720845.
doi: 10.3389/fonc.2022.720845. eCollection 2022.

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

Ismail Siti Mariam  1 , Ramli Norhidayah  1 , Abu Bakar Zulaikha  1 , Mohd Yunus Nazihah  1 , Hassan Rosline  2 , Ghazali Anis Kausar  3 , Sulong Sarina  1 , Husin Azlan  4 , Ravindran Ankathil  1
Affiliations

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

Ismail Siti Mariam et al. Front Oncol. .

Abstract

The emergence of additional chromosome abnormalities (ACAs) in chronic myeloid leukemia (CML) patients during treatment with a tyrosine kinase inhibitor (TKI) regime is generally associated with resistance to treatment and a sign of disease progression to accelerated phase or blast phase. We report the type, frequency, and differential prognostic impact of stratified ACAs with treatment response in 251 Malaysian CML patients undergoing TKI therapy. ACAs were observed in 40 patients (15.9%) of which 7 patients (17.5%) showed ACAs at time of initial diagnosis whereas 33 patients (82.5%) showed ACAs during the course of IM treatment. In order to assess the prognostic significance, we stratified the CML patients with ACAs into four groups, group 1 (+8/+Ph), group 2 (hypodiploidy), group 3 (structural/complex abnormalities); group 4 (high-risk complex abnormalities), and followed up the disease outcome of patients. Group 1 and group 2 relatively showed good prognosis while patients in group 3 and group 4 had progressed or transformed to AP or blast phase with a median survival rate of 12 months after progression. Novel ACAs consisting of rearrangements involving chromosome 11 and chromosome 12 were found to lead to myeloid BP while ACAs involving the deletion of 7q or monosomy 7 led toward a lymphoid blast phase. There was no evidence of group 2 abnormalities (hypodiploidy) contributing to disease progression. Compared to group 1 abnormalities, CML patients with group 3 and group 4 abnormalities showed a higher risk for disease progression. We conclude that the stratification based on individual ACAs has a differential prognostic impact and might be a potential novel risk predictive system to prognosticate and guide the treatment of CML patients at diagnosis and during treatment.

Keywords: additional chromosome abnormalities (ACAs); chronic myeloid leukemia; disease progression; imatinib mesylate; resistance; stratification.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Complex karyotype (patient #26) showing 46,XX,t(9;22)(q34;q11),t(3;15;21)(q25;q22;q22) pattern. (B) Complex karyotype (patient # 37) showing 44,X,-Y,t(9;22)(q34;q11),del(12)(p12),der(13;21)(q10;q10) pattern.
Figure 2
Figure 2
(A, B) CML patients with different groups of ACAs (group 1, group 2, group 3, and group 4) and their overall survival rate.
Figure 3
Figure 3
(A, B) CML patients with different groups of ACAs (group 1, group 2, group 3, and group 4) and their respective of progression-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1–positive chronic myeloid leukemia. Blood (2009) 113(8):1619–30. doi: 10.1182/blood-2008-03-144790 - DOI - PMC - PubMed
    1. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol (2016) 34(24):2851–7. doi: 10.1200/jco.2015.66.2866 - DOI - PubMed
    1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 355(23):2408–17. doi: 10.1056/NEJMoa062867 - DOI - PubMed
    1. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al. . A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias. Blood (2002) 100(6):1965–71. doi: 10.1182/blood-2001-12-0181 - DOI - PubMed
    1. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. . Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd annual meeting of the American society of hematology, Orlando, FL, December 11, 2001. Blood (2002) 99(10):3530–9. doi: 10.1182/blood.V99.10.3530 - DOI - PubMed